Listen on Apple Podcasts Badge
deezer-icon
castro-34
stitcher logo
Spotify
AmazonMusic_button_black_RGB_5X
Google Podcasts Badge
audible logo
I heart media badge
pocketcasts_small_light@2x
streaming-live-post-icon

Imaginostics is a health tech startup developing a breakthrough longevity technology for precision medicine located in Lake Nona Medical City, Orlando, FL. The company’s QUTE-CE MRI methodology provides vascular imaging biomarkers that can non-invasively assay vascular structure and function in high resolution anywhere in the body, providing clinicians and scientists new endpoints for early detection and enhanced characterization of complex diseases.

Codi Amir Gharagouzloo, MSc, PhD, Scientific Founder & CEO
Codi developed the technology as a Postdoctoral Fellow for two years at the Gordon Center for Medical Imaging at Massachusetts General Hospital & Harvard Medical School before founding the company to translate the technology from bench to bedside. He invented the imaging modality while pursuing his PhD in Bio-Engineering and has an extensive background in imaging and engineering, holding a Master’s of Science degree in BioPhotonics and dual Bachelor degrees in Mechanical & Nuclear Engineering and Physics. He enjoys bike riding, the gym, and playing board games with his family. If given another lifespan, he would go on a space exploration adventure like Captain Jean-Luc Picard in Star Trek.

Valerie Aimee Gharagouzloo, Esq., Co-Founder & COO
Valerie is a New York attorney. Her background is in International Human Rights Law and U.S. Immigration Law. She is an advocate for affordable medical care for all. Valerie’s youngest brother grew up with only one kidney and a rare uncurable disease of the peripheral nervous system, with unknown cause and symptoms similar to diabetic neuropathy. Valerie and Codi have been married for 13 years and have two beautiful children. In her role as COO, Valerie is outreaching to our first pharma clients to offer our services for accelerating drug development – especially for novel drugs that improve vascular biology. She is also reaching out to potential investors and partners to bring our breakthrough longevity technology to market.

*E – explicit language may be used in this podcast.